Patents by Inventor Rachel T. Nishimura
Rachel T. Nishimura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897900Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: December 18, 2020Date of Patent: February 13, 2024Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Publication number: 20220315604Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: ApplicationFiled: December 18, 2020Publication date: October 6, 2022Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Publication number: 20220281823Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.Type: ApplicationFiled: May 5, 2022Publication date: September 8, 2022Applicant: Janssen Pharmaceutica NVInventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods, Anne M. Fourie, Xiaohua Xue
-
Patent number: 11427601Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: August 30, 2021Date of Patent: August 30, 2022Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Patent number: 11345666Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.Type: GrantFiled: June 17, 2019Date of Patent: May 31, 2022Assignee: Janssen Pharmaceutica NVInventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods
-
Patent number: 10975057Abstract: The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.Type: GrantFiled: June 17, 2019Date of Patent: April 13, 2021Assignee: Janssen Pharmaceutica NVInventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Anne M. Fourie, Xiaohua Xue
-
Patent number: 10975037Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.Type: GrantFiled: June 17, 2019Date of Patent: April 13, 2021Assignee: Janssen Pharmaceutica NVInventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Craig R. Woods, Ronald L. Wolin, William M. Jones, Anne M. Fourie, Xiaohua Xue
-
Patent number: 10947252Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: August 19, 2019Date of Patent: March 16, 2021Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Publication number: 20200055874Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: ApplicationFiled: August 19, 2019Publication date: February 20, 2020Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Publication number: 20190382373Abstract: The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.Type: ApplicationFiled: June 17, 2019Publication date: December 19, 2019Applicant: Janssen Pharmaceutica NVInventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Anne M. Fourie, Xiaohua Xue
-
Publication number: 20190382349Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.Type: ApplicationFiled: June 17, 2019Publication date: December 19, 2019Applicant: Janssen Pharmaceutica NVInventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Craig R. Woods, Ronald L. Wolin, William M. Jones, Anne M. Fourie, Xiaohua Xue
-
Publication number: 20190382354Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.Type: ApplicationFiled: June 17, 2019Publication date: December 19, 2019Applicant: Janssen Pharmaceutica NVInventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods, Anne M. Fourie, Xiaohua Xue